NIH R01 · 2025
Targeting jmjd3 mitigates heterotopic ossification
PROJECT SUMMARY/ABSTRACT Heterotopic ossification (HO) is the pathologic formation of extra-skeletal that is always preceded by an inflammatory insult and occurs in ~20% of patients after hip arthroplasty, burns or musculoskeletal injury. Currently, no therapeutics or physical therapy-based protocols exist to prevent or treat HO. In this regard, there is a void in our understanding of the molecular mechanisms underlying HO formation and progression. We present data that the histone demethylase, JMJD3, is increased in HO macrophages (Mφs) resulting in persistent production of transforming growth factor-beta (TGFꞵ1) at the HO injury site. This excess TGFꞵ1 causes aberrant mesenchymal…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.